Shandong Linuo Pharmaceutical Packaging Co., Ltd. (SHE:301188)
China · Delayed Price · Currency is CNY 31.84
+0.07 (0.22%)
Sep 14, 2026, 3:04 PM CST
SHE:301188 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,142 | 966.08 | 1,055 | 924.39 | 767.42 | 881.32 |
Other Revenue | 14.03 | 15.39 | 25.73 | 22.97 | 54.6 | 7.56 |
| 1,156 | 981.47 | 1,081 | 947.37 | 822.02 | 888.88 | |
Revenue Growth | 13.44% | -9.19% | 14.09% | 15.25% | -7.52% | 34.67% |
Cost of Revenue | 915.46 | 782.59 | 884.89 | 787.73 | 646.56 | 670.42 |
Gross Profit | 240.22 | 198.88 | 195.95 | 159.64 | 175.47 | 218.46 |
Selling, General & Admin | 151.23 | 114.16 | 87.03 | 67.7 | 49.69 | 49.81 |
Research & Development | 37.77 | 34.37 | 33.8 | 30.13 | 25.96 | 32.5 |
Other Operating Expenses | 0.63 | -4.74 | 1.22 | 2.61 | 5.79 | 6.29 |
Operating Expenses | 192.84 | 145.3 | 123.36 | 102.68 | 81.48 | 90.95 |
Operating Income | 47.38 | 53.58 | 72.59 | 56.96 | 93.99 | 127.51 |
Interest Expense | -20.65 | -26.74 | -25.81 | -9.04 | - | -0.99 |
Interest & Investment Income | 12.92 | 14.35 | 18.59 | 16.27 | 15.04 | 6.21 |
Currency Exchange Gain (Loss) | -4.35 | -0.18 | 2.04 | -0.02 | 5.62 | -2.2 |
Other Non Operating Income (Expenses) | -3.29 | -1.39 | -0.56 | -0.85 | 0.44 | -0.07 |
EBT Excluding Unusual Items | 32.01 | 39.63 | 66.85 | 63.33 | 115.08 | 130.45 |
Gain (Loss) on Sale of Investments | 1.04 | 1.67 | 1.45 | 2.15 | 1.35 | - |
Gain (Loss) on Sale of Assets | 4.46 | 2.4 | 0.03 | 0.05 | 0.47 | 0.45 |
Asset Writedown | -0.05 | -0.01 | -0.65 | -0.05 | -0.01 | -0.07 |
Other Unusual Items | 6.61 | 5.53 | 3.76 | 7.33 | 9.83 | 9.45 |
Pretax Income | 44.06 | 49.22 | 71.45 | 72.81 | 126.72 | 140.27 |
Income Tax Expense | 14.21 | 9.56 | 5.38 | 6.89 | 10.07 | 15.49 |
Net Income | 29.85 | 39.66 | 66.07 | 65.92 | 116.65 | 124.78 |
Net Income to Common | 29.85 | 39.66 | 66.07 | 65.92 | 116.65 | 124.78 |
Net Income Growth | -46.46% | -39.97% | 0.23% | -43.49% | -6.51% | 37.42% |
Shares Outstanding (Basic) | 249 | 233 | 228 | 235 | 233 | 178 |
Shares Outstanding (Diluted) | 249 | 233 | 228 | 235 | 233 | 178 |
Shares Change | 10.78% | 2.40% | -3.23% | 0.91% | 30.88% | 2.08% |
EPS (Basic) | 0.12 | 0.17 | 0.29 | 0.28 | 0.50 | 0.70 |
EPS (Diluted) | 0.12 | 0.17 | 0.29 | 0.28 | 0.50 | 0.70 |
EPS Growth | -51.67% | -41.38% | 3.57% | -44.00% | -28.57% | 34.62% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -442.39 | -306.5 | -86.55 | -52.04 | -115.99 | -20.91 |
Free Cash Flow Per Share | -1.77 | -1.31 | -0.38 | -0.22 | -0.50 | -0.12 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.200 | 0.200 |
Dividend Growth | 0% | 0% | 0% | -50.00% | 0% | - |
Gross Margin | 20.79% | 20.26% | 18.13% | 16.85% | 21.35% | 24.58% |
Operating Margin | 4.10% | 5.46% | 6.72% | 6.01% | 11.43% | 14.34% |
Profit Margin | 2.58% | 4.04% | 6.11% | 6.96% | 14.19% | 14.04% |
Free Cash Flow Margin | -38.28% | -31.23% | -8.01% | -5.49% | -14.11% | -2.35% |
EBITDA | 183.39 | 179.73 | 178.44 | 139.55 | 159.27 | 182.64 |
EBITDA Margin | 15.87% | 18.31% | 16.51% | 14.73% | 19.38% | 20.55% |
D&A For EBITDA | 136.01 | 126.15 | 105.85 | 82.59 | 65.28 | 55.14 |
EBIT | 47.38 | 53.58 | 72.59 | 56.96 | 93.99 | 127.51 |
EBIT Margin | 4.10% | 5.46% | 6.72% | 6.01% | 11.43% | 14.34% |
Effective Tax Rate | 32.26% | 19.42% | 7.53% | 9.46% | 7.94% | 11.04% |
Revenue as Reported | 1,156 | 981.47 | 1,081 | 947.37 | 822.02 | 888.88 |
Advertising Expenses | - | 11.58 | 4.42 | 2.72 | 0.33 | 0.58 |